New drug moxidectin tested for safer river blindness treatment in thousands
NCT ID NCT04311671
First seen Feb 05, 2026 · Last updated May 05, 2026 · Updated 12 times
Summary
This study tested the safety of a single dose of moxidectin compared to ivermectin in nearly 13,000 people living in areas with river blindness (onchocerciasis). Some participants also received albendazole for a related infection. The goal was to see if moxidectin causes fewer or less severe side effects. Results will help determine if moxidectin can be a safer treatment option for controlling this parasitic disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ONCHOCERCIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Suisse de Recherches Scientifiques en Coˆte d'Ivoire
Abidjan, Côte d’Ivoire
-
Centre de Recherche pour les Maladies Tropicales Negligees
Rethy, Ituri, Democratic Republic of the Congo
Conditions
Explore the condition pages connected to this study.